扶正抗癌方联合mFOLFOX4化疗方案治疗进展期胃癌临床研究

Fuzhengkang'ai Prescription Combined with mFOLFOX4 Chemotherapy in Treatment of Advanced Gastric Cancer

目的:探讨扶正抗癌方联合mFOLFOX4化疗方案对进展期胃癌患者的临床疗效。方法:选取68例胃癌进展期患者为研究对象,随机将其分为对照组(34例),研究组(34例),对照组给予mFOLFOX4方案化疗,研究组在对照组的基础上采用扶正抗癌方联合治疗,比较两组治疗效果,治疗前后中医证候积分、肿瘤坏死因子(tumor necrosis factor-α,TNF-α)水平及生存质量变化情况,同时记录不良反应发生率。结果:研究组缓解率优于对照组,差异具有统计学意义(P<0.05);治疗前两组患者中医证候积分及TNF-α水平比较,差异无统计学意义(P>0.05),治疗后均显著降低(P<0.05),研究组显著低于对照组(P<0.05);治疗前两组患者躯体功能、角色功能、认知功能、情绪功能、社会功能评分比较,差异无统计学意义(P>0.05),治疗后均显著升高(P<0.05),研究组显著高于对照组(P<0.05);研究组化疗不良反应发生率为5.88%,显著低于对照组的26.47%(P<0.05)。结论:扶正抗癌方联合mFOLFOX4化疗方案治疗进展期胃癌可有效缓解患者临床症状,减少化疗不良反应,提高患者生存质量。

Objective ：To examine the clinical effacacy of Fuzhengkang＇ai Prescription combined with mFOLFOXg chemotherapy in treatment of advanced Gastric Cancer. Methods ：68 cases of patients with advancing Gastric Cancer in our hospital were randomly divided into control group （34 cases） and study group （34 cases）. The control group was given mFOLFOXd chemotherapy in treatment, while the study group was given Fuzhengkang＇ai Prescription based on that of the control group. The treatment efficacies were compared between the two groups. The changes of TCM syndrome scores, tumor necrosis factor （TNF-α） levels, patients＇ quality of life, and the incidence rates of adverse reactions of both groups were recorded and compared. Results ： The treatment effi- cacy and the total remission rate of the study group were significantly better than those of the control group respectively （P 〈 0. 05 ）. The differences in the TCM syndrome scores and TNF-αlevels between the two groups before treatment were not statistically significant （P 〉 0.05）, both of which significantly decreased after treatment （P 〈 0.05） and that of the study group was signifi- cantly lower than that of the control group （ P 〈 0.05 ）. The scores of physical function, role function, cognitive function, emotionalfunction and social function between both groups were not significant differently respectively before treatment （ P 〉 0.05 ）, while all of these indicators significantly increased after treatment （ P 〈 0.05 ）, and the scores of the study group were significantly higher than those of the control group （ P 〈 0.05 ）. The incidence rate of adverse reactions of the study group was 4.65 %, which was sig- nificantly lower than that （20.93 % ） of the control group （P 〈 0.05 ）. Conclusion： Fuzhengkang＇ ai Prescription combined with mFOLFOX4 chemotherapy can effectively alleviate the clinical symptoms of patients with advanced Gastric Cancer, which can re- duce the side effects of chemotherapy and improve patients＇ quality of life and has good application prospect.